Old Web
English
Sign In
Acemap
>
authorDetail
>
Ruishan Wu
Ruishan Wu
Center for Global Development
Medicine
Placebo
Pharmacology
Tolerability
Pharmacokinetics
5
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A randomized phase 1 single-dose polysomnography study of ASP8062, a GABAB receptor positive allosteric modulator.
2021
Psychopharmacology
Mark Walzer
Ruishan Wu
Maha Ahmad
Jon Freeman
Gary Zammit
Gerard J. Marek
Show All
Source
Cite
Save
Citations (1)
Single‐ and Multiple‐Dose Safety, Tolerability, and Pharmacokinetic Profiles of ASP8062: Results From 2 Phase 1 Studies
2020
Clinical pharmacology in drug development
Mark Walzer
Gerard J. Marek
Ruishan Wu
Masanori Nagata
David Han
Show All
Source
Cite
Save
Citations (4)
Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects.
2020
Clinical pharmacology in drug development
Peter L. Bonate
Charles Van Sant
Kathy Cho
Erin C. Zook
Larry R Smith
Sou Boutsaboualoy
Ming Ye
Xuegong Wang
Ruishan Wu
Anne Koester
Diane Rammelsberg
Ronald Goldwater
Thomas Marbury
Show All
Source
Cite
Save
Citations (0)
Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.
2020
Clinical Pharmacokinectics
Amit Desai
Lauren Benner
Ruishan Wu
Lev Gertsik
Tolga Uz
Gerard J. Marek
Tong Zhu
Show All
Source
Cite
Save
Citations (1)
Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia.
2020
Neuropsychopharmacology
Amit Desai
Lauren Benner
Ruishan Wu
Lev Gertsik
Paul Maruff
Gregory A. Light
Tolga Uz
Gerard J. Marek
Tong Zhu
Show All
Source
Cite
Save
Citations (6)
1